Reverse and structural vaccinology approach to design a highly immunogenic multi-epitope subunit vaccine against Streptococcus pneumoniae infection

• Published in: Infection, genetics and evolution Vol. 85; p. 104473
• Main Authors: Mamede, Lohany Dias, de Paula, Keila Gonçalves, de Oliveira, Bianca, dos Santos, Janete Soares Coelho, Cunha, Lucas Maciel, Junior, Moacyr Comar, Jung, Lenice Roteia Cardoso, Taranto, Alex Gutterres, de Oliveira Lopes, Débora, Leclercq, Sophie Yvette
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2020
• Subjects: Multi-epitope protein antigen; Reverse vaccinology; Streptococcus pneumoniae; Structural vaccinology; Multi-epitope protein antigen; Reverse vaccinology; Streptococcus pneumoniae; Structural vaccinology
• ISSN: 1567-1348; 1567-7257
• DOI: 10.1016/j.meegid.2020.104473

Streptococcus pneumoniae is a pathogen that resides in the upper respiratory tract of healthy individuals, maintaining a commensal relationship with its host. However, the virulent form may be the etiology of pneumonia, meningitis, bacteremia, and other respiratory tract infections. Streptococcal diseases are preventable by vaccination; but currently available vaccines have some drawbacks, especially due to the high capsule variability of streptococci strains. Thus, an effective prevention strategy continues to be the focus of extensive research. In our work, several bioinformatics tools were used to identify immunogenic peptides from a selected pool of 46 conserved proteins from Streptococcus pneumoniae. In silico analysis showed that 10 proteins had epitopes with affinity for B and T lymphocytes, which were present in at least 26 different pathogens serotypes and were considered promiscuous. The multi-epitope protein, designated HC44, was designed based on these epitopes and specific linkers to improve stability and exposure to T lymphocytes. The recombinant HC44 protein was expressed in E.coli and Swiss-Webster mice were immunised by intraperitoneal injection. Immunisation with the multi-epitope HC44 protein resulted in the production of very high levels of IgG with title superior to 1/1.200.000. However, subtype IgG was highly unbalanced toward IgG1 and no protection was afforded after challenge with S.pneumoniae in a sepsis model. Thus, our strategy has been effective in constructing a highly antigenic protein but novel immunisation strategies should be investigated to reorient the immune system toward a protective response. •Need to develop a vaccine with cross-protection between S.pneumoniae serotypes.•Design and production of a multi-epitopes subunit vaccine which was highly immunogenic in vivo.•IgG title production >1.000.000.•Further research required to improve the type of immune response and protection induced.